CU2 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelCerus’ consumable-based INTERCEPT model can generate repeat revenue as blood centers and hospitals process ongoing component volumes. This recurring use pattern supports revenue visibility, embeds the technology in routine workflows, and provides a durable foundation for expansion as adoption increases.
Sustained Revenue GrowthDouble-digit product growth across the first half and raised full-year guidance indicate continued commercial expansion rather than reliance on a single quarter. Sustained demand growth can improve operating leverage, strengthen market presence, and support investment in new applications.
Improving Earnings TrajectoryRepeated positive adjusted EBITDA and lower expected interest expense represent meaningful progress toward stronger internal cash generation. Although GAAP profitability has not yet been reached, this trajectory can improve financial flexibility and reduce the earnings burden from financing costs.
Bears Say
GAAP Losses And Weak Cash ConversionCerus remains dependent on continued execution before its improving operating trend becomes durable GAAP profitability. Ongoing net losses and weak recent cash conversion can constrain reinvestment, increase reliance on financing, and make the business more vulnerable if growth moderates.
Elevated LeverageDebt exceeding equity leaves Cerus with less balance-sheet flexibility than a conservatively financed company. Leverage can absorb a meaningful portion of future cash flow through debt service and interest costs, limiting the resources available for product development, commercialization, or unexpected setbacks.
Margin And Adoption HeadwindsLower gross margins show that revenue growth is not translating fully into profitability, while very limited Asia-Pacific penetration and unresolved regulatory reviews make expansion there uncertain. These factors may delay scale benefits and require sustained commercial and regulatory investment.
Cerus News
CU2 FAQ
What was Cerus Corp’s price range in the past 12 months?
Currently, no data Available
What is Cerus Corp’s market cap?
Cerus Corp’s market cap is CHF403.45M.
When is Cerus Corp’s upcoming earnings report date?
Cerus Corp’s upcoming earnings report date is Nov 02, 2026 which is in 3 days.
How were Cerus Corp’s earnings last quarter?
Cerus Corp released its earnings results on Jul 30, 2026. The company reported -CHF0.008 earnings per share for the quarter, beating the consensus estimate of -CHF0.011 by CHF0.002.
Is Cerus Corp overvalued?
According to Wall Street analysts Cerus Corp’s price is currently Undervalued.
Does Cerus Corp pay dividends?
Cerus Corp does not currently pay dividends.
What is Cerus Corp’s EPS estimate?
Cerus Corp’s EPS estimate is >-0.01.
How many shares outstanding does Cerus Corp have?
Cerus Corp has 201,524,900 shares outstanding.
What happened to Cerus Corp’s price movement after its last earnings report?
Cerus Corp reported an EPS of -CHF0.008 in its last earnings report, beating expectations of -CHF0.011. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cerus Corp?
Currently, no hedge funds are holding shares in CH:CU2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cerus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF3.73 (― Upside)
CHF3.73 (― Upside)
Blogger Sentiment
Bullish
CH:CU2 Sentiment 100%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
61.33%
12-Months-Change
Fundamentals
Return on Equity
-10.31%
Trailing 12-Months
Asset Growth
-3.70%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cerus Corp
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
CU2 Company Deck
CU2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive momentum: double-digit product revenue growth, raised product and IFC guidance, consecutive quarters of positive adjusted EBITDA, meaningful debt refinancing benefits, regulatory progress (PMA submission and upcoming Phase 3 readout), and a clean quality audit. Counterbalancing items include a drop in gross margin (51.4% vs 55.2% prior year) driven by currency and inflationary pressures, reduced government contract revenue this quarter, modest operating cash use for inventory, and regulatory/penetration challenges in Asia-Pacific and for broader IFC adoption. On balance the positives (top-line growth, improving profitability measures, stronger balance sheet flexibility, and regulatory/clinical progress) outweigh the near-term headwinds.View all CH:CU2 earnings summariesCU2 Stock 12 Month Forecast
Average Price Target
―Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Outset Medical
―
908 Devices
―